TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23561636

Group type: EXPERIMENTAL
Intervention: Microbial cell preparation (Hexbio(®)) containing fructooligosaccharide, Bifidobacterium and Lactobacillus, consumed twice daily for 7 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo, consumed twice daily for 7 days
Number of subjects: 120
Study: 21566547

Group type: EXPERIMENTAL
Intervention: Skin protection cream containing glycerol, vaseline, and liquid paraffin, applied twice a day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Vaseline ointment, applied twice a day
Number of subjects: 54
Study: 19481749

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided cannulation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tactile sensation cannulation
Number of subjects: 50
Study: 16513607

Group type: EXPERIMENTAL
Intervention: Dynamic 18F‐FET PET studies (0‐40 min after injection of 180 MBq of 18F‐FET)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Time to peak analysis
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: SUV90‐to‐background ratio for single‐frame evaluation of the early‐uptake phase
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard method (SUVmax)
Number of subjects: 45

Group type: COMPARATOR
Intervention: SUVmax‐to‐background ratio
Number of subjects: 45
Study: 15351769

Group type: EXPERIMENTAL
Intervention: Topiramate (25 mg/d to 300 mg/d)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 11262672

Group type: EXPERIMENTAL
Intervention: Amblyopia (defined as best-corrected visual acuity of 6/9 or worse in the absence of any pathological cause)
Number of subjects: 4721

Group type: EXPERIMENTAL
Intervention: Amblyopic cases
Number of subjects: 4721

Group type: EXPERIMENTAL
Intervention: Amblyopic eyes
Number of subjects: 4721

Group type: EXPERIMENTAL
Intervention: Amblyopic group
Number of subjects: 4721

Group type: COMPARATOR
Intervention: Normal population
Number of subjects: 4721
Study: 9244750

Group type: EXPERIMENTAL
Intervention: Dobutamine echocardiography (DE)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Exercise electrocardiography (EE)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Combination strategy of DE and EE
Number of subjects: 208
Study: 8229497

Group type: EXPERIMENTAL
Intervention: Chlorpromazine plus lorazepam (30 mg/m2 chlorpromazine and 0.04 mg/kg lorazepam, both given intravenously)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Chlorpromazine alone (30 mg/m2 given intravenously)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional antiemetic therapy
Number of subjects: 25
Study: 7149452

Group type: EXPERIMENTAL
Intervention: Plugged telescoping catheter (PTC) brush
Number of subjects: 19

Group type: COMPARATOR
Intervention: Single sheathed nonplugged catheter brush
Number of subjects: 19
Study: 30946883

Group type: EXPERIMENTAL
Intervention: Low alcohol dose (0.4 g/kg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High alcohol dose (0.6 g/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 29021119

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Psycho-Education (PE)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 69
Study: 26507388

Group type: EXPERIMENTAL
Intervention: 6 weeks supervised preoperative rehabilitation program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hospital standard preoperative management
Number of subjects: 40
Study: 23932671

Group type: EXPERIMENTAL
Intervention: Birth position on the seat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-adherers (control group)
Number of subjects: 0
Study: 20536371

Group type: EXPERIMENTAL
Intervention: von Langenbeck with intravelar veloplasty
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Furlow palate repair
Number of subjects: 673

Group type: COMPARATOR
Intervention: Millard cheiloplasty
Number of subjects: 673

Group type: COMPARATOR
Intervention: Spina lip repair
Number of subjects: 673

Group type: COMPARATOR
Intervention: Age at palatoplasty (9 to 12 months or 15 to 18 months)
Number of subjects: 673
Study: 19427572

Group type: EXPERIMENTAL
Intervention: Music listening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 17719311

Group type: EXPERIMENTAL
Intervention: Beta-blockers (maximal tolerated doses)
Number of subjects: 314
Study: 16271820

Group type: EXPERIMENTAL
Intervention: Colored photos
Number of subjects: 0

Group type: COMPARATOR
Intervention: Black and white (grey-scaled) photos
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colored drawings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Black and white (grey-scaled) drawings
Number of subjects: 0
Study: 13677579

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 120

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 120
Study: 10340913

Group type: EXPERIMENTAL
Intervention: Thalidomide (200 mg/day, administered for 21 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Thalidomide coadministration
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Thalidomide administration
Number of subjects: 10
Study: 7617861

Group type: EXPERIMENTAL
Intervention: Three-dimensional fast spin-echo MR cholangiopancreatography
Number of subjects: 37
Study: 2043220

Group type: EXPERIMENTAL
Intervention: Captopril (ACE inhibitor); specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; no adverse metabolic effects reported.
Number of subjects: 0
Study: 6178649

Group type: EXPERIMENTAL
Intervention: exogenous interferon alpha (Le) (3 x 10(6) IU/ml, 1 drop daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: albumin
Number of subjects: 14
Study: 31862195

Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza HA vaccine (QIV)
Number of subjects: 270
Study: 30712432

Group type: EXPERIMENTAL
Intervention: MADIT-RIT specific settings
Number of subjects: 232982

Group type: COMPARATOR
Intervention: MADIT-RIT settings
Number of subjects: 232982

Group type: EXPERIMENTAL
Intervention: ≥185 beats per minute or delay ≥6 seconds
Number of subjects: 232982

Group type: EXPERIMENTAL
Intervention: High-rate cutoff programming
Number of subjects: 232982

Group type: EXPERIMENTAL
Intervention: Generic programming parameters
Number of subjects: 232982
Study: 29171468

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day (Group 1)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Gliclazide MB 60 mg/day (Group 2)
Number of subjects: 51
Study: 25948124

Group type: EXPERIMENTAL
Intervention: Conventional treatment plus yangxinkang tablets for 4 weeks
Number of subjects: 228

Group type: COMPARATOR
Intervention: Conventional Western treatment (Control)
Number of subjects: 228
Study: 23170757

Group type: EXPERIMENTAL
Intervention: Active Living Every Day (ALED)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 280
Study: 21258820

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.125%
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 84
Study: 19088168

Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16292334

Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Topical lidocaine‐prilocaine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 18
Study: 14585880

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (800 microg)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Vaginal misoprostol (800 microg)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Both routes of administration
Number of subjects: 224
Study: 10755498

Group type: EXPERIMENTAL
Intervention: Clinical vignettes
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standardized patients (SPs)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Chart abstraction
Number of subjects: 98
Study: 8811737

Group type: EXPERIMENTAL
Intervention: Chemical crosslinking of lysine groups in vimentin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linkages between dimers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Molecular modeling of vimentin conformations
Number of subjects: 0
Study: 1419813

Group type: EXPERIMENTAL
Intervention: GM‐CSF
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 61
Study: 6724715

Group type: EXPERIMENTAL
Intervention: Cimetidine (histamine H2-receptor blocker)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 31188268

Group type: EXPERIMENTAL
Intervention: Ivabradine (15 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 29982532

Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: fractional-dose IPV (fIPV)
Number of subjects: 309

Group type: COMPARATOR
Intervention: No IPV Vaccine (Control)
Number of subjects: 309
Study: 26501464

Group type: EXPERIMENTAL
Intervention: Higher von Willebrand factor (vWF) activity
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Lower high-density lipoprotein cholesterol
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Higher thromboxane B2 levels
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Higher NT-pro-BNP levels
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Lower vWF activity
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Lower total cholesterol
Number of subjects: 65
Study: 24598526

Group type: EXPERIMENTAL
Intervention: Locomotor training (average of 45 training sessions, 5 days/week, 1 hour/day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Locomotor training
Number of subjects: 16
Study: 21765374

Group type: EXPERIMENTAL
Intervention: MVR blade trocar
Number of subjects: 40

Group type: COMPARATOR
Intervention: Beveled trocar
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 20200239

Group type: EXPERIMENTAL
Intervention: Envelope genes
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Non-envelope genes
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: HVR1 sequences
Number of subjects: 6
Study: 17568167

Group type: EXPERIMENTAL
Intervention: NPH
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Glargine
Number of subjects: 52
Study: 15696331

Group type: EXPERIMENTAL
Intervention: BCAA/TRP mixture (60 g BCAA and 2 g TRP)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 11210069

Group type: EXPERIMENTAL
Intervention: AST > or = 800 microIU
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: AST > or = 1,200 microIU
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: BOP
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Negative AST test result
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: AST diagnostic criteria
Number of subjects: 41
Study: 10205352

Group type: EXPERIMENTAL
Intervention: Tube feeding (tube +)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (tube -)
Number of subjects: 129
Study: 7933535

Group type: EXPERIMENTAL
Intervention: Antibiotic plus fluconazole therapy (FLCZ group)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Antibiotic therapy only (antibiotic group)
Number of subjects: 62
Study: 2964212

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.5 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29576488

Group type: EXPERIMENTAL
Intervention: Single-use fully disposable and patient-specific cutting guides (SU)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Traditional patient-specific cutting guides (PSI)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional instrumentation (CI)
Number of subjects: 70
Study: 28452904

Group type: EXPERIMENTAL
Intervention: Gastrin-releasing peptide (GRP) 160 pmol/kg for 4 consecutive days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gastrin-releasing peptide (GRP)
Number of subjects: 10
Study: 26577690

Group type: EXPERIMENTAL
Intervention: RESTORE web-based intervention
Number of subjects: 19
Study: 24252674

Group type: EXPERIMENTAL
Intervention: Oral carbohydrate (500 ml administered 2-3 hours before anesthesia)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral placebo (500 ml administered 2-3 hours before anesthesia)
Number of subjects: 60
Study: 21145284

Group type: EXPERIMENTAL
Intervention: Radiotherapy (50 Gy in 25 fractions over 5 weeks)
Number of subjects: 1694

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg daily for 5 years)
Number of subjects: 1694

Group type: COMPARATOR
Intervention: No adjuvant treatment (Control group)
Number of subjects: 1694
Study: 18332190

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 412

Group type: COMPARATOR
Intervention: Successful aging educational control intervention
Number of subjects: 412
Study: 16525219

Group type: EXPERIMENTAL
Intervention: Atrial-based pacing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ventricular-based pacing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pacemaker therapy
Number of subjects: 0
Study: 12685882

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg twice daily for 2 weeks
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg twice daily for 4 weeks
Number of subjects: 114
Study: 10574419

Group type: EXPERIMENTAL
Intervention: Irbesartan 75 mg/HCTZ 12.5 mg
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg/HCTZ 12.5 mg
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study: 8908379

Group type: EXPERIMENTAL
Intervention: Glimepiride 8 mg once daily (q.d.)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Glimepiride 4 mg twice daily (b.i.d.)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Glimepiride 16 mg once daily (q.d.)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Glimepiride 8 mg twice daily (b.i.d.)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study: 1918423

Group type: EXPERIMENTAL
Intervention: Estazolam 2.0 mg
Number of subjects: 99
Study: 6196549

Group type: EXPERIMENTAL
Intervention: acebutolol (with PAA)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: sotalol (without PAA)
Number of subjects: 39

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 39
Study: 29729848

Group type: EXPERIMENTAL
Intervention: 28-gene hypoxia-related mRNA signature
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Post-prostatectomy radiotherapy
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Definitive radiotherapy alone
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Pooled cohort analysis
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Hypoxia-modifying therapy (carbogen and nicotinamide)
Number of subjects: 130
Study: 26520230

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 1498

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 1498
Study: 24926075

Group type: EXPERIMENTAL
Intervention: Combination therapy plus acupuncture for 3 months
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard combination therapy
Number of subjects: 2
Study: 23160438

Group type: EXPERIMENTAL
Intervention: Monocular viewing with unrestricted field of view (FOV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Binocular viewing with unrestricted FOV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monocular viewing with moderately restricted FOV (40 degrees)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monocular viewing with severely restricted FOV (11.5 degrees)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Binocular viewing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monocular viewing
Number of subjects: 0
Study: 19639415

Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel (60, 90 or 120 mg)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 18940558

Group type: EXPERIMENTAL
Intervention: Botulinum injection followed by physiotherapy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (10 age/sex-matched controls)
Number of subjects: 8
Study: 15975126

Group type: EXPERIMENTAL
Intervention: Stabilization splint therapy (Group I)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pivot splint therapy (Group II)
Number of subjects: 40
Study: 12689686

Group type: EXPERIMENTAL
Intervention: Ibandronate 2.5 mg taken 30 minutes before breakfast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibandronate 2.5 mg taken 60 minutes before breakfast
Number of subjects: 0
Study: 10628043

Group type: EXPERIMENTAL
Intervention: Nasal lavage using gravity fed, home‐made unbuffered isotonic saline for 2 months
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Nasal lavage
Number of subjects: 46
Study: 8528172

Group type: EXPERIMENTAL
Intervention: MPC infusion (1, 10, and 50 x 10(6) MPCs)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ex vivo culture expansion of MPCs
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Bone marrow examination 2 weeks post-infusion
Number of subjects: 23
Study: 1835139

Group type: EXPERIMENTAL
Intervention: Goserelin plus flutamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Goserelin alone
Number of subjects: 0
Study: 6753446

Group type: EXPERIMENTAL
Intervention: Femoxetine (200 mg in the first week, 300 mg in the remaining weeks for 12 weeks)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 6209476

Group type: EXPERIMENTAL
Intervention: Ibopamine 200 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ibopamine 300 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dopamine 2-4 micrograms/kg/min
Number of subjects: 9
Study: 30029684

Group type: EXPERIMENTAL
Intervention: Hippocampal avoidance whole brain radiotherapy (HA-WBRT), 30 Gy in 10 fractions, treated in 4 centers.
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Hippocampal avoidance whole brain radiotherapy (HA-WBRT)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Whole brain radiotherapy (WBRT)
Number of subjects: 215
Study: 26831602

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Warm-water irrigation
Number of subjects: 287

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 287
Study: 25276626

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation along with regular medicine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual care (budesonide and formoterol)
Number of subjects: 48
Study: 22928076

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 250,000 IU
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21316541

Group type: EXPERIMENTAL
Intervention: Test formulation of nevirapine 200-mg tablet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference formulation of nevirapine 200-mg tablet
Number of subjects: 20
Study: 19000527

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention program consisting of two medical visits and a nurse visit for health education, along with two letters and two telephone calls.
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 79
Study: 15860282

Group type: EXPERIMENTAL
Intervention: PPV with ILM removal
Number of subjects: 12

Group type: COMPARATOR
Intervention: Modified grid laser photocoagulation
Number of subjects: 12
Study: 12442030

Group type: EXPERIMENTAL
Intervention: rG-CSF (5 microg/kg/dose i.v. twice a day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: rhuGM-CSF (4 microg/kg/dose i.v. twice a day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 10865688

Group type: EXPERIMENTAL
Intervention: Computer-based contraceptive decision aid
Number of subjects: 949
Study: 7782815

Group type: EXPERIMENTAL
Intervention: Role of the staff nurse and specially trained nurse facilitator in decision making
Number of subjects: 0
Study: 1954661

Group type: EXPERIMENTAL
Intervention: American ginseng compound liquor (treated group)
Number of subjects: 71

Group type: COMPARATOR
Intervention: American ginseng liquor only (control group)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study: 7466522

Group type: EXPERIMENTAL
Intervention: Marker perfusion method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple aspiration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple aspiration with marker correction
Number of subjects: 0
Study: 31336101

Group type: EXPERIMENTAL
Intervention: mHealth wheelchair skills training program
Number of subjects: 18

Group type: COMPARATOR
Intervention: tablet gaming control
Number of subjects: 18
Study: 28532408

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) administered at 2 days and 1 year postoperatively
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline only)
Number of subjects: 60
Study: 25398399

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided continuous thoracic paravertebral block (USG-PVB)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Continuous epidural block (TEB) with fentanyl and ropivacaine
Number of subjects: 90
Study: 22538838

Group type: EXPERIMENTAL
Intervention: Part-time sick leave
Number of subjects: 171

Group type: COMPARATOR
Intervention: Full-time sick leave
Number of subjects: 171
Study: 21219551

Group type: EXPERIMENTAL
Intervention: Artesunate and Mefloquine (fixed dose combination)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Artesunate and Mefloquine (loose tablets)
Number of subjects: 50
Study: 18466266

Group type: EXPERIMENTAL
Intervention: 10 mg tadalafil
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: 20 mg tadalafil
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study: 16484450

Group type: EXPERIMENTAL
Intervention: Estrogen treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined analysis of observational and clinical trial data
Number of subjects: 0
Study: 12622770

Group type: EXPERIMENTAL
Intervention: Paroxetine, 20 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16